B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting

References

• LeBien TW, Tedder TF. B-lymphocytes: how they develop and function. Blood112, 1570–1579 (2008).
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev.223, 284–299 (2008).
   PubMed Web of Science ®Google Scholar
• Bouaziz JD, Yanaba K, Venturi GM et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc. Natl. Acad. Sci. USA104, 20882–20887 (2007).
   Google Scholar
• Lund FE. Cytokine-producing B lymphocytes – key regulators of immunity. Curr. Opin. Immunol.20, 1–7 (2008).
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med.358, 676–688 (2008).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing–remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol.63, 395–400 (2008).
   PubMed Web of Science ®Google Scholar
• McFarland HF. The B cell – old player, new position on the team. N. Engl. J. Med.358, 664–665 (2008).
   PubMed Web of Science ®Google Scholar
• Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol.4, 557–567 (2008).
   PubMedGoogle Scholar
• Uchida J, Lee Y, Hasegawa M et al. Mouse CD20 expression and function. Int. Immunol.16, 119–129 (2004).
   PubMed Web of Science ®Google Scholar
• Uchida J, Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med.199, 1659–1669 (2004).
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med.203, 743–753 (2006).
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Xiu Y, Poe JC et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV. Blood112, 1205–1213 (2008).
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol.169, 954–966 (2006).
   PubMed Web of Science ®Google Scholar
• Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St. Clair EW, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol.179, 1369–1380 (2007).
   PubMed Web of Science ®Google Scholar
• Xiu Y, Wong CP, Hamaguchi Y et al. B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes in NOD mice despite isotype-specific differences in FcγR effector functions. J. Immunol.180, 2863–2875 (2008).
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Hamaguchi Y, Ueda Y et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol.180, 361–371 (2008).
   PubMed Web of Science ®Google Scholar
• Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J. Invest. Dermatol.128, 2850–2858 (2008).
   PubMed Web of Science ®Google Scholar
• Stasi R, Del Poeta G, Stipa E et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood110, 2924–2930 (2007).
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Bhan AK. A case for regulatory B cells. J. Immunol.176, 705–710 (2006).
   PubMed Web of Science ®Google Scholar
• Serra P, Santamaria P. To ‘B’ regulated: B cells as members of the regulatory workforce. Trends Immunol.27, 7–10 (2006).
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol.8, 391–397 (2008).
   PubMed Web of Science ®Google Scholar
• Bouaziz J-D, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev.224, 201–214 (2008).
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity28, 639–650 (2008).
   PubMed Web of Science ®Google Scholar
• Matsushita T, Yanaba K, Bouaziz J-D, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest.118, 3420–3430 (2008).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest.116, 2393–2402 (2006).
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest.116, 2385–2392 (2006).
   PubMed Web of Science ®Google Scholar
• Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med.184, 2271–2278 (1996).
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol.3, 944–950 (2002).
   PubMed Web of Science ®Google Scholar
• Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum.56, 2715–2718 (2007).
   PubMed Web of Science ®Google Scholar
• Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis.13, 1365–1368 (2007).
   PubMed Web of Science ®Google Scholar
• Benedetti L, Franciotta D, Vigo T et al. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti-myelin-associated glycoprotein polyneuropathy. Arch. Neurol.64(10), 1531–1533 (2007).
   PubMedGoogle Scholar
• Duddy M, Niino M, Adatia F et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol.178, 6092–6099 (2007).
   PubMed Web of Science ®Google Scholar
• Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann. Neurol.64, 187–199 (2008).
   PubMed Web of Science ®Google Scholar
• Kurosaki T. Paradox of B cell-targeted therapies. J. Clin. Invest.118, 3260–3263 (2008).
   PubMed Web of Science ®Google Scholar
• StClair WE, Tedder TF. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum.54, 1–9 (2006).
   PubMedGoogle Scholar